OnDosis announces commitment of 30 MSEK raise from owners and DIG Investment

GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag. 

Nyhetens sammanfattning: 

Följt av ingående av ett avtal med ett ledande Business-to-Business läkemedelsföretag, meddelar OnDosis AB, som är ett spin-off från AstraZeneca, att det har erhållit åtaganden för en kapitalisering om 30 MSEK från befintliga ägare och DIG Investment.

Resterande pressmeddelande följer på engelska: 

..............................................................

Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, AstraZeneca Medtech spin-off OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.

OnDosis today announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.

The commitment follows a successful signing of a strategic partnership agreement between OnDosis and Tiefenbacher Group. With the partnership and raise, OnDosis will be able to execute the near-term growth agenda; initially focusing on bringing OnDosis’ ADHD drug/device combination currently in development to the market in the US. This followed by potential initiation of several other drug/device combinations for diseases which require individual dosing and benefit from combining traditional drug-based therapies with digital therapeutics.

OnDosis is uniquely positioned in the convergence between personalized medicine and digital therapeutics. Based on the rapidly growing demand for personalizing medicine and applying digital technologies to healthcare delivery, OnDosis plan to raise additional funds in the coming year.

Martin Olovsson, CEO of OnDosis says: “We are excited to have continued support from current strategic owners, among them AstraZeneca and Boston Consulting Group, and a new financial investor, DIG Investment, to back our ambitious growth agenda. With the breakthrough agreement with Tiefenbacher Group, we will now accelerate in building critical team capabilities and conclude final steps in the development of our first product launch anticipated in the coming years.”

For more information, please contact:

Martin Olovsson, CEO OnDosis 
Phone +46 76 772 85 01
E-mail: m.olovsson@ondosis.com 

About OnDosis:

Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent. Visit ondosis.com!

About DIG Investment:

DIG Investment is an investment office focused on direct investments in the global alternatives markets. DIG Investment was founded 2011 by Martin HP Söderström to source, analyse and structure investments in special situations - many whom relate to the disrupting technology sector. Today DIG Investment has a group of anchor families as investors and have further widened the field of opportunities in the alternatives space to include additional areas. Such as, consumer brands, shared economies, retail, hospitality (many related to real-estate), media, software, consumer electronics and environmental/sustainability. Most still related to the core families' main businesses. www.diginvestment.com